Spain Tops Europe in Clinical Trials, Attracting €834M Investment in 2023
Spain has emerged as the top destination for clinical trials in Europe, attracting significant investment and driving job creation. In 2024, Spain led Europe with 930 new approvals, particularly in oncology and innovative modalities. This success can be attributed to its early adoption of EU regulations and cost-effective structure.
Spain's growth in clinical trials began with its full implementation of the EU Clinical Trials Regulation in 2016, becoming the first European country to do so. This was further bolstered by Royal Decree 1090/2015, which harmonised and simplified national procedures. These moves streamlined the process, making Spain an attractive location for trials.
The country's low cost structure has also played a significant role. Over 50% of investment in Spain's clinical research goes towards early and complex Phase I and II trials, indicating the confidence investors have in the country's capabilities. In 2023, the pharmaceutical industry invested over €834 million in clinical research in Spain, reflecting this trust.
The growth of clinical trials in Spain has led to job creation in various sectors. Research institutions, logistics, IT, and administration all benefit from the increased activity. Jan Enderlein, head of CRO FGK GmbH, highlighted Spain's leadership in an interview with European Biotechnology at BioSpain in 2024. While France and Germany follow Spain in Europe, globally, China and the United States lead the way.
Spain's strategic approach to clinical trials, including early adoption of EU regulations and a cost-effective structure, has positioned it as the leading location for clinical trials in Europe. This has resulted in significant investment and job creation, with 930 new approvals in 2024. As the global landscape continues to evolve, Spain's commitment to innovation and streamlined processes ensures its competitive edge.
